Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

16/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	3.17M 2.74M 2.53M 2.37M 4.43M 302M 4.5M 29.83M 11.63M 147M 11.91M 11.66M 509M	P/E Ratio 2024	-5.27x	P/E Ratio 2025	-3.28x
Enterprise Value	3.92M 3.38M 3.12M 2.92M 5.47M 372M 5.55M 36.8M 14.35M 181M 14.69M 14.38M 627M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

16/05	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
05/03	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03/03	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
17/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI
11/02	Bioxytran reports positive phase 2 results demonstrating rapid viral clearance with Prolectin-Mbioxytran	RE
11/02	Bioxytran, Inc. Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with Prolectin-Mbioxytran	CI
03/02	Bioxytran, Inc. and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics	CI
15/12	Bioxytran, Inc. Announces Resignation of Anders Utter from Board of Directors and Chair of Audit Committee	CI
15/11	Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Bioxytran, Inc. announced that it has received $0.43 million in funding	CI

29/05	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
21/03	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ
05/03	Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M	AQ
24/02	Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus	AQ
18/02	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement	AQ

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	01/09/2018
Ola Soderquist DFI	Director of Finance/CFO	65	01/09/2018
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	02/11/2018
Alan Hoberman BRD	Director/Board Member	73	02/11/2018
David Platt CHM	Chairman	73	01/09/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.03%	+2.30%	+55.91%	+114.22%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+44.91%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-21.68%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+403.86%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-30.62%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.30%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+176.72%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+205.26%	11.15B
Average	+1.80%	+2.09%	+27.72%	+106.67%	23.75B
Weighted average by Cap.	+1.72%	+2.37%	+32.04%	+99.60%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.04M -1.88M -1.76M -3.3M -225M -3.36M -22.24M -8.67M -109M -8.88M -8.69M -379M	-2.12M -1.83M -1.69M -1.58M -2.96M -202M -3.01M -19.95M -7.78M -98.22M -7.97M -7.8M -340M
Net Debt	1.09M 941K 867K 811K 1.52M 104M 1.54M 10.23M 3.99M 50.38M 4.09M 4M 174M	741K 640K 590K 552K 1.03M 70.41M 1.05M 6.96M 2.71M 34.27M 2.78M 2.72M 119M

End-of-day quote Other OTC Other stock markets
- ^USD	-